Identification and Mechanism of the PD-1/PD-L1 Genomic Signature SORL1 as Protective Factor in Bladder Cancer

Background: Immunotherapy has recently shown remarkable efficacy for advanced bladder cancer patients. Accordingly, identifying a biomarker associated with the programmed cell death protein 1 (PD-1)/its ligand (PD-L1) genomic signature to predict patient prognosis is necessary. Methods: In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yajing, Chen, Didi, Shen, Lanxiao, Huang, Xiaowei, Chen, Yi, Su, Huafang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716752/
https://www.ncbi.nlm.nih.gov/pubmed/34976002
http://dx.doi.org/10.3389/fgene.2021.736158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716752/
https://www.ncbi.nlm.nih.gov/pubmed/34976002
http://dx.doi.org/10.3389/fgene.2021.736158

Ejemplares similares